Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus TRAVASOL 8 5 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus TRAVASOL 8 5 W O ELECTROLYTES.
AMINOSYN 3.5% M IN PLASTIC CONTAINER vs TRAVASOL 8.5% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% M is a mixture of essential and non-essential amino acids used for parenteral nutrition. It provides substrates for protein synthesis, thereby maintaining nitrogen balance and supporting tissue repair and growth.
TRAVASOL 8.5% W/O ELECTROLYTES provides amino acids for protein synthesis, serving as a source of nitrogen and essential amino acids to support anabolism and prevent catabolism in patients unable to tolerate oral or enteral nutrition.
Intravenous infusion: 500 mL to 1 L of 3.5% amino acid solution per day for adults; rate not to exceed 0.1 g amino acids/kg/hr.
Intravenous infusion; 500 mL to 1 L per day, administered at a rate of 100-200 mL/hour. Dosage depends on protein and calorie requirements, typically 0.8-1.5 g/kg/day of amino acids.
None Documented
None Documented
Variable (minutes to hours) due to rapid metabolic utilization; terminal half-life in plasma is <10 minutes for most amino acids.
Not applicable as a single value; amino acids have variable half-lives (minutes to hours) depending on individual metabolic demand and plasma concentration; continuous infusion achieves steady state rapidly.
Renal: >90% as amino acids and metabolites; negligible biliary/fecal elimination.
Primarily eliminated via metabolic pathways (hepatic deamination and transamination) with nitrogenous waste excreted renally as urea; negligible biliary/fecal excretion of unchanged amino acids.
Category C
Category C
Amino Acid Solution
Amino Acid Solution